Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

Blum, William, Klisovic, Rebecca B., Hackanson, Bjoern, Liu, Zhongfa, Liu, Shujun, Devine, Hollie, Vukosavljevic, Tamara, Huynh, Lenguyen, Lozanski, Gerard, Kefauver, Cheryl, Plass, Christoph, Devine, Steven M., Heerema, Nyla A., Murgo, Anthony, Chan, Kenneth K., Grever, Michael R., Byrd, John C., Marcucci, Guido·2007·Journal of Clinical Oncology

Abstract

Purpose: To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML). Patients and Methods: Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received decitabine alone for 10 days. To determine the MTD, 11 patients received decitabine (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21). Results: The OBD of decitabine was 20 mg/m 2/d intravenously, with limited nonhematologic toxicity. In patients treated with decitabine plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P ≤ .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for decitabine alone or with VA. Conclusion: Low-dose decitabine was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of decitabine (20 mg/m 2/d for 10 days) alone or with an alternative deacetylating agent are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.09.4169

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 315

Metadata

Authors
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S. M., Heerema, N. A., Murgo, A., Chan, K. K., Grever, M. R., Byrd, J. C., & Marcucci, G.
Venue
Journal of Clinical Oncology
Published
2007-09-01
Volume
25
Issue
25
Pages
3884-3891
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1963919702
Cited by
315
References
35
FWCI
15.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2006.09.4169
The paper
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S. M., Heerema, N. A., Murgo, A., Chan, K. K., Grever, M. R., Byrd, J. C., & Marcucci, G. (2007). Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.4169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.